Main menu

FEATURED

In recent years, the prices charged for specialty drugs have become a source of concern for many policymakers. Such drugs typically treat chronic, complex, or rare conditions, frequently have high prices, and may require special handling or patient monitoring. They accounted for a growing share of total net drug spending from 2010 to 2015 in both Medicare’s prescription drug benefit (Part D) and Medicaid. The net prices paid for specialty drugs are much higher in Medicare Part D than in Medicaid, and net spending on such drugs grew much faster in Medicare Part D than in Medicaid.

QUICK LINKS

ABOUT CBO

CBO is strictly nonpartisan; conducts objective, impartial analysis; and hires its employees solely on the basis of professional competence without regard to political affiliation. CBO does not make policy recommendations, and each report and cost estimate summarizes the methodology underlying the analysis.